The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Momenta Pharmaceuticals has an asset utilization ratio of 6.8 percent. This suggests that the company is making $0.068 for each dollar of assets. An increasing asset utilization means that Momenta Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
How important is Momenta Pharmaceuticals's Liquidity
Momenta Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Momenta Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Momenta Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Momenta Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Momenta Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Momenta Pharmaceuticals's total debt and its cash.
Detailed Perspective On Momenta Pharmaceuticals
Earning per share calculations of Momenta Pharmaceuticals is based on official Zacks consensus of 4 analysts regarding Momenta Pharmaceuticals' future annual earnings. Given the historical accuracy of 80.98%, the future earnings per share of the company is estimated to be -1.6086 with the lowest and highest values of -1.8 and -1.48, respectively. Please note that this consensus of annual earnings estimates for the firm is an estimate of EPS before non-recurring items and including employee stock options expenses.
Is Momenta a risky opportunity?
Let's check the volatility. Momenta is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Momenta (NASDAQ:MNTA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Momenta Pharmaceuticals stock makes you a part-owner of that company.
Momenta Pharmaceuticals Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Momenta Pharmaceuticals. The Momenta consensus assessment is calculated by taking the average estimates from all of the analysts covering Momenta Pharmaceuticals
| Strong Buy | 6 | 75.0 |
| Buy | 0 | 0.0 |
| Hold | 2 | 25.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Momenta technical analysis suggests possible throwback
Momenta Pharmaceuticals jensen alpha is up to 0.0. Momenta Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Momenta Pharmaceuticals individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Momenta Pharmaceuticals future systematic risk.
Our Final Take On Momenta Pharmaceuticals
Whereas some other firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Momenta Pharmaceuticals may offer a potential longer-term growth to investors. The bottom line, as of the 10th of August 2020, our primary 30 days buy-or-sell advice on the company is
Sell. However, we believe Momenta Pharmaceuticals is
undervalued with
very small odds of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Momenta Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
